Laccure®Pessary meets the needs of women suffering from bacterial vaginosis, a hidden health problem with reduced quality of life
October 1, 2015
The new non-prescription product Laccure® Pessary is a breakthrough women’s health product that is effective, safe and user-friendly, addressing the unmet needs of the 300 million women suffering from bacterial vaginosis (BV) every year.
Results from a web-based survey of 2,660 women in the US, UK and Germany show that BV, with an odorous vaginal discharge as the most pronounced symptom, is a common and hidden health problem affecting daily life, often connected with embarrassment, guilt and humiliation. 56% of the women had recurring problems, once or several times a year, and 24% did not seek any treatment. The product-related improvements most often wished for were less frequent administration and smear-free products.
“Laccure® Pessary represents a considerable commercial potential in the OTC market and is ready to be launched. We are aiming to find a partner with resources for efficient commercialisation to ensure that women are offered care and treatment that meets their needs,” says Dr Jeanette Robertsson, CEO, participant at the XXI FIGO World Congress of Gynaecology and Obstetrics, October 4 – 9 in Vancouver, Canada (www.figo2015.org).
Bacterial Vaginosis is the most common vaginal infection in women of childbearing age. Today, there is a lack of effective and safe products that are also user-friendly and can be dosed with low frequency. BV is an imbalance in the vaginal bacterial flora, resulting in a lack of vaginal acidity, discharge with a pronounced foul odour and inhibition of normal lactobacilli growth. Frequent recurrences are common.
Laccure® Pessary is a new, patented product based on a proprietary substance that releases lactic acid over several days in order to decrease the elevated vaginal pH. The developmental work has focused on creating a user-friendly, non-smear product that is easy to insert and highly effective. This has been demonstrated in clinical studies in which 80% of the women were free of their BV after a single dose (www.heraldopenaccess.us/journals/Infectious-&-Non-Infectious-Diseases/current-issue.php).
Laccure® Pessary is CE-marked as a Class IIa medical device that only needs to be administered once to treat BV and once a month to prevent recurrence. It is now ready for market introduction in the EU/EES countries.
Laccure AB is a project company within P.U.L.S.
www.laccure.com and www.pulsinvest.se
Jeanette Robertsson, CEO, email@example.com
Sven-Inge Svensson, Chairman of the Board, firstname.lastname@example.org